• Depth & Technique: Inject into the mid-to-deep dermis or subcutaneous plane using linear threading, fanning, cross-hatching, retrograde delivery, or bolus placement based on anatomical zone. Avoid overcorrection.
• Anesthesia: Administer topical, local, or regional anesthesia separately before injection if needed, as this formulation lacks lidocaine.
• Safety & Aspiration: Maintain strict aseptic technique and assess vascular risk. Aspiration may be used to reduce risk, but should not be solely relied upon to confirm extravascular placement.
• Post-Treatment: Gently massage immediately after injection for even distribution, if clinically appropriate. Advise patients to avoid sun exposure, extreme heat, alcohol, and strenuous activity until redness, swelling, or tenderness resolves.
• Key Warnings: Vascular occlusion, skin necrosis, visual disturbance/blindness, delayed nodule formation, transient bruising, and injection-site edema.

• Indicated for the correction of deep to very deep facial wrinkles and folds, including nasolabial folds, marionette lines, perioral rhytids, and glabellar lines, depending on local labeling and clinical assessment.
• Indicated for facial volume restoration and contouring in areas such as the cheeks, chin, and jawline, using deep dermal or subcutaneous injection techniques as appropriate.
• May be used for facial rejuvenation in areas with volume loss or laxity-related contour changes that require mid- to deep-plane correction.
• Suited to versatile use across multiple facial zones and injection depths, supported by the BI-FLEX® rheological profile and syringe ergonomics.
• Intended for administration by licensed aesthetic medicine professionals only and is not for self-administration.

Product Specifications

• Active ingredient: Cross-linked hyaluronic acid 24 mg/g; mannitol 9 mg/mL as an antioxidant stabilizer.
• Format: Injectable gel supplied in 2 × 1 mL prefilled glass, sterile, latex-free syringes with 4 × 27G ½ needles.
• Manufacturer: Laboratoires VIVACY, France.
• Drug class: Injectable cross-linked hyaluronic acid dermal filler; Class III medical device; non-animal origin; no lidocaine.
• Technology: IPN-Like Technology™ with interpenetrated cross-linked networks; BI-FLEX® ergonomic syringe system.
• Regulatory status: CE-marked Class III medical device, CE Marking No. 0499; US FDA status should be verified by jurisdiction before procurement.
• Also known as: STYLAGE® L Bi-SOFT®.

Contraindications

• Do not administer to patients with known hypersensitivity to hyaluronic acid, mannitol, or any excipient in the formulation.
• Do not inject into areas with active skin infection, inflammation, open wounds, or untreated lesions at the intended treatment site.
• Use caution in patients with autoimmune conditions, a history of severe allergic reactions, or previous complications with injectable dermal fillers; assess individually before treatment.
• Avoid use during pregnancy or breastfeeding as a precaution, due to limited safety data in these populations.
• Assess patients using anticoagulants, antiplatelet agents, NSAIDs, or supplements that may increase bleeding risk, as bruising, bleeding, or hematoma may be more likely.

STYLAGE® L BI-FLEX® is intended for deep dermal or subcutaneous injection only; do not inject superficially. Before treatment, practitioners must screen for contraindications, document any known allergies to hyaluronic acid or excipients, and evaluate the patient for active infection, inflammation, bleeding risk, or prior filler complications.

• Preparation: Bring the syringe to room temperature prior to administration to ensure optimal gel flow and minimize injection force. Under aseptic conditions, securely attach the provided 27G ½” needle.
• Inspection: Inspect the gel before use. Do not administer if the syringe is damaged, the sterile seal is compromised, or the gel appears cloudy, discolored, or non-uniform.
• Anesthesia: Because this formulation contains no co-formulated lidocaine, topical, local, or regional anesthesia may be applied separately at the practitioner’s discretion.
• Disposal: Single-use only. Safely discard any remaining gel, the needle, and the syringe immediately after the procedure, in accordance with biohazard protocols. Do not re-sterilize or reuse.

Legal & Regulatory Status

STYLAGE® L BI-FLEX® is a CE-marked Class III medical device manufactured by Laboratoires VIVACY (France). Its regulatory status in other jurisdictions, including the United States, should be verified before procurement. Practitioners who wish to buy dermal fillers or buy STYLAGE® may contact the Med Supply Solutions support team for sourcing information and documentation support.

1. Wu Y, Ascher B, Yang Z, et al. Effectiveness and Safety of a Cross-linked Hyaluronic Acid Plus Mannitol Filler for the Correction of Nasolabial Folds in Chinese Subjects: A Randomized, Blinded, Controlled Study. Aesthet Surg J. 2026;46(5):466-477. doi:10.1093/asj/sjaf186
2. Converset-Viethel S, Dobosz M, Baspeyras M, Skretkowicz-Szarmach K, Schlaudraff KU. Effectiveness and Safety of STYLAGE® L Lidocaine in the Treatment of Nasolabial Folds (NICE Study): A Randomized, Double-Blind, Split-Face Controlled Study. Aesthetic Plast Surg. 2025;49(24):6846-6857. doi:10.1007/s00266-025-05105-2

The contents of this page are meant for licensed medical professionals. They serve informational purposes only and are not to be taken as medical advice.